HC Wainwright Brokers Increase Earnings Estimates for RLAY

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Equities research analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Relay Therapeutics in a research note issued on Monday, November 9th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.56) per share for the year, up from their prior estimate of ($1.57). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.55) EPS.

Several other equities research analysts also recently weighed in on the company. Wall Street Zen raised Relay Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. The Goldman Sachs Group lifted their target price on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Canaccord Genuity Group assumed coverage on shares of Relay Therapeutics in a research report on Thursday, July 16th. They issued a “buy” rating and a $29.00 price target for the company. Finally, Barclays increased their price target on shares of Relay Therapeutics from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $27.00.

Relay Therapeutics Stock Down 2.1%

RLAY opened at $19.96 on Wednesday. The firm has a market cap of $4.41 billion, a price-to-earnings ratio of -13.22 and a beta of 1.74. Relay Therapeutics has a 52 week low of $5.95 and a 52 week high of $21.27. The business’s 50 day moving average is $18.38 and its two-hundred day moving average is $15.32.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Wednesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03.

Institutional Investors Weigh In On Relay Therapeutics

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Relay Therapeutics in the second quarter valued at about $286,042,000. Perceptive Advisors LLC boosted its holdings in Relay Therapeutics by 412.3% in the 1st quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock valued at $97,024,000 after purchasing an additional 7,847,896 shares in the last quarter. Spruce Street Capital LP purchased a new stake in Relay Therapeutics in the 2nd quarter valued at approximately $55,832,979. Dimensional Fund Advisors LP increased its position in Relay Therapeutics by 18.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,940,536 shares of the company’s stock worth $29,248,000 after purchasing an additional 460,186 shares during the period. Finally, Bank of America Corp DE acquired a new position in Relay Therapeutics during the 2nd quarter worth approximately $50,425,000. 96.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Relay Therapeutics news, insider Peter Rahmer sold 4,508 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $20.03, for a total transaction of $90,295.24. Following the completion of the sale, the insider directly owned 223,657 shares of the company’s stock, valued at $4,479,849.71. This represents a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $18.10, for a total value of $872,401.90. Following the sale, the chief executive officer directly owned 471,301 shares of the company’s stock, valued at $8,530,548.10. The trade was a 9.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,149,344 shares of company stock worth $119,185,625 over the last quarter. 5.04% of the stock is owned by insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.